Skip to main content
Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Irritable Bowel Syndrome Is Associated with an Increased Risk of Dementia: A Nationwide Population-Based Study

  • Chien-Hua Chen,

    Affiliations Digestive Disease Center, Show-Chwan Memorial Hospital, Changhua, Taiwan, Hungkuang University, Taichung, Taiwan, Meiho University of Technology, Pingtung, Taiwan

  • Cheng-Li Lin,

    Affiliations Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan, College of Medicine, China Medical University, Taichung, Taiwan

  • Chia-Hung Kao

    Affiliations Graduate Institute of Clinical Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan, Department of Nuclear Medicine and PET Center, China Medical University Hospital, Taichung, Taiwan



Abnormal interaction in the brain–gut axis has emerged as one of the relevant pathophysiological mechanisms for the development of irritable bowel syndrome (IBS). Moreover, the brain–gut axis has recently been demonstrated to be crucial for the maintenance of cognitive performance. Therefore, we assessed the risk of dementia following diagnosis of IBS.


Using the Taiwan National Health Insurance Research Database (NHIRD) to obtain medical claims data from 2000 to 2011, we employed a random sampling method to enroll32 298 adult patients with IBS and frequency-matched them according to sex, age, and baseline year with 129 192 patients without IBS.


The patients with IBS exhibited an increased risk of dementia [adjusted hazard ratio (aHR) = 1.26, 95% confidence interval (CI) = 1.17–1.35]after adjustment for age, sex, diabetes, hypertension, stroke, coronary artery disease (CAD), head injury, depression, and epilepsy, and the overall incidence of dementia for the cohorts with and without IBS was 4.86 and 3.41 per 1000 person-years, respectively. IBS was associated with an increased risk of dementia in patients older than 50 years in both male and female, and in those with comorbidity or without comorbidity. After adjustment for age, sex, and comorbidity, patients with IBS were also more likely to develop either non- Alzheimer’s disease (AD) dementia (aHR = 1.24, 95% CI = 1.15–1.33) or AD (aHR = 1.76, 95% CI = 1.28–2.43).


IBS is associated with an increased risk of dementia, and this effect is obvious only in patients who are ≥50 years old.


Irritable bowel syndrome (IBS) is characterized by recurrent abdominal pain or discomfort with altered visceral hypersensitivity or gastrointestinal (GI) motility. Evidence supports that a diagnosis of IBS can be confidently made for the patients fitting the symptoms-based criteria and having no concerning features for organic diseases, including symptom onset after age 50, severe or progressively worsening symptoms, unexplained weight loss, nocturnal diarrhea, GI bleeding, unexplained iron-deficiency anemia, and family history of colonic cancer, celiac disease, or inflammatory bowel disease [1]. Some organic changes with altered inflammatory markers, dysbiosis, and genotypic expressions of inflammatory or neurotransmitter receptor molecules indeed can be observed in the IBS patients by employing more sensitive methods [2]. However, most IBS patients will have a negative evaluation result if they have no concerning features. IBS is a common functional GI disorder worldwide, and it accounts for approximately 11%–22.1% of cases in GI outpatient departments for Chinese populations [3,4]. Patients with IBS have greater risk for comorbidities, either constitutional or mental illness, resulting in a decline in quality of life and increase in medical expenditure [57]. The microbiome—brain—gut axis is composed of the central nervous system, neuroendocrine and neuroimmune systems, autonomic nervous system, enteric nervous system (ENS), and gut microbiome [8]. The brain can influence motility, sensation, and secretion in the GI tract via signaling between neurons, hormones, and cytokines. Moreover, the GI tract can modulate brain function reciprocally through the same mechanism [8, 9].

Dementia can be classified into non-Alzheimer’s disease (AD) dementia and AD. The etiological factors of dementia remain undetermined despite genetic, vascular, and psychological disorders being implicated as possible risk factors. AD is the most common pattern of dementia, and most patients with AD are older than 65 years. AD exhibits the characteristics of insidious onset and a clear-cut history of worsening cognition without substantial concomitant cerebrovascular disease. In addition to the criteria for dementia, the certainty of AD can be enhanced in the presence of pathophysiological processes such as biomarkers of brain amyloid-beta protein deposition, downstream neuronal degeneration, or injury. Dementia can cause cognitive or behavioral symptoms such as functional interference at work or during usual activities, and decline from previous levels of functioning and performing without delirium or major psychiatric disorders [10]. Dementia has a substantial impact on patients and their family, exerting a considerable burden on both direct and indirect social expenditures.

To assess the association between IBS and the subsequent development of dementia, this study adopted a nationwide population-based cohort design to analyze data from the National Health Insurance Research Database (NHIRD) in Taiwan.


Data Source

This study was conducted using data from the Longitudinal Health Insurance Database 2000 (LHID2000), which contains the original claims data of 1 000 000 randomly sampled persons from the 2000 Registry for Beneficiaries (23.75 million citizens). The National Health Insurance (NHI) program is a nationwide single-payer insurance system that was established in March 1995 and has covered nearly 99% of the population of people in Taiwan [11]. The electronic medical files contain details on utilities and health care services provided to individual patients, including demographic characteristics, complete outpatient visits, hospital admissions, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnostic codes, prescriptions, and clinical orders(such as surgery). To comply with data privacy regulations, personally identifiable information is encrypted and all data are depersonalized.

Sampled Participants

Using the LHID2000, we identified patients aged ≥20 years with newly diagnosed IBS (ICD-9-CM Code 564.1) between 2000 and 2011. The index date was set as the date of initial diagnosis of IBS. A non-IBS comparison cohort was randomly selected among patients without a diagnosis of IBS during 2000–2011, and these patients were frequency-matched with the patients with IBS at a ratio of 1:4according to age group (every 5 years), sex, and index year. The index date for the comparison cohort was randomly appointed a month and day with the same index year of the matched IBS cases. Patients with a history of dementia (ICD-9-CMCodes 290, 294.1, and 331.0) or with missing medical information were excluded from both cohorts.

Outcome and Comorbidities

We identified the first diagnosis of dementia (ICD-9-CM Codes 290, 294.1, and 331.0) as the study end point. All cases were followed from the index date until the occurrence of dementia or December 31, 2011, and observations on the last date were regarded as censored observations. We defined baseline comorbidities, namely diabetes (ICD-9-CMCode250), hypertension (ICD-9-CMCodes401-405), stroke (ICD-9-CMCodes430-438), coronary artery disease(CAD) (ICD-9-CMCodes410-414), head injury (ICD-9-CMCodes850-854 and 959.01), depression (ICD-9-CMCodes296.2, 296.3, 300.4, and 311), and epilepsy (ICD-9-CMCode345).

Ethics Statement

The National Health Research Institute (NHRI) encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Patient consent is not required to access the NHIRD. This study was approved to be exempted by the Institutional Review Board (IRB) of China Medical University and Hospital (CMUH104-REC2-115). The IRB specifically waived the consent requirement.

Data Availability Statement

All data and related metadata were deposited in an appropriate public repository. The data on the study population that were obtained from the NHIRD ( are maintained in the NHIRD ( The NHRI is a nonprofit foundation established by the government. The use of the data needs the assessment and agreement by NHRI.

Statistical Analysis

The distribution of age (20–34, 35–49, 50–64, and ≥65 years), sex, and comorbidity were compared between the two cohorts by using the chi-squared test for the categorical variables and the Student’s ttest for the continuous variables. Cumulative incidence curves for dementia were plotted using the Kaplan—Meier method, and the differences in cumulative incidence between the two cohorts were tested using a log rank test. Dementia incidence densities were estimated by dividing the number of dementiacases by the number of person-years in each risk factor, and then stratified by age, sex, and comorbidity. Univariateand multivariate Cox proportion hazard regression models were employed to examine the effect of IBS on the risk of dementia, expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). The multivariate Cox models were adjusted for age, sex, and comorbidities of diabetes, hypertension, stroke, CAD, head injury, depression, and epilepsy. When the patients were stratified according to age, sex, and comorbidity, the relative risk of dementia in the IBS cohort compared with the non-IBS cohort was also analyzed using Cox models. All analyses were performed using SAS Version 9.4 (SAS Institute, Cary, NC, USA). The significance level was set at less than 0.05 for the two-tailed P value.


Table 1 shows the demographic characteristics and comorbidities in cohorts with and without IBS. The study examined a cohort of 32 298 patients with IBS and a non-IBS cohort of 129 192 patients. Both cohorts had similar age and sex distributions, and were predominantly ≤49 years old (48.7%) and female (52.6%). The mean agesof the IBS and non-IBS cohorts were 51.5 [standard deviation (SD) = 16.4]and 51.0 (SD = 16.6) years, respectively. Compared with the non-IBS cohort, the IBS cohort exhibited higher prevalence in all comorbidities at the baseline (p < 0.001). During the mean follow-up of 6.89 years for the IBS cohort and 6.78 years for the non-IBS cohort, the results of Kaplan—Meier analysis showed that the IBS cohort exhibited a higher cumulative incidence of dementia (log-rank test, p < 0.001) (Fig 1).

Fig 1. Cummulative incidence comparison of dementia for patients with (dashed line) or without (solid line) Irritable bowel syndrome.

Table 1. Demographic characteristics and comorbidities in cohorts with and without irritable bowel syndrome.

Table 2 shows the incidence and HR for dementia and dementia-associated risk factors. The overall incidence of dementia for the cohorts with and without IBS was 4.86 and 3.41 per 1000 person-years, respectively. After adjustment for age, sex, and comorbidities of diabetes, hypertension, stroke, CAD, head injury, depression, and epilepsy, the patients with IBS exhibited an increased risk of dementia relative to those without IBS[adjusted HR(aHR) = 1.26, 95% CI = 1.17–1.35]. The dementia incidence increased with age and tended to coincide with comorbidity incidence. Compared with patients who were ≤49 years old, the risk of dementia was 13.0-fold higher in those aged 50–64 years (95% CI = 10.2–16.7), and 85.5-fold higher in those aged ≥65 years (95% CI = 67.4–108.5). Besides, the multivariate models also showed that dementia was independently associated with each comorbidity, such as diabetes (aHR = 1.27, 95% CI = 1.17–1.37), hypertension (aHR = 1.41, 95% CI = 1.30–1.51), stroke (aHR = 1.65, 95% CI = 1.49–1.83), CAD (aHR = 1.22, 95% CI = 1.14–1.30), head injury (aHR = 1.61, 95% CI = 1.37–1.88), depression (aHR = 1.77, 95% CI = 1.58–1.98), and epilepsy (aHR = 1.88, 95% CI = 1.48–2.38).

Table 2. Incidence and Hazard ratio for dementia and dementia-associated risk factors.

Table 3 shows the incidence of dementia stratified by age, sex and comorbidity and Cox model measured HR for patients with IBS compared those without IBS. Except for patients aged 49 years and younger, the patients with IBS were significantly associated with an increased risk of dementia compared with the patients without IBS in two age groups (age 50–64 years, aHR = 1.34, 95% CI = 1.12–1.60; age, >65 years, aHR = 1.24, 95% CI = 1.14–1.34), both female(aHR = 1.16, 95% CI = 1.05–1.28) and male (aHR = 1.37, 95% CI = 1.24–1.52), and patients with(aHR = 1.43, 95% CI = 1.12–1.68) and without comorbidity (aHR = 1.29, 95% CI = 1.20–1.40).

Table 3. Incidence of dementia stratified by age, sex and comorbidity and Cox model measured hazard ratiofor patients with irritable bowel syndrome compared those without irritable bowel syndrome.

Table 4 shows the HRs of non-AD dementia and AD in association with gender, age, IBS and dementia-related comorbidities in univariate and multivariate Cox regression models. Compared with the non-IBS cohort, the patients with IBS were 1.76-fold more likely to develop AD (95% CI = 1.28–2.43) and exhibited a significantly higher risk of non-AD dementia (aHR = 1.24, 95% CI = 1.15–1.33). However, IBS may be less influential than other risk factors, such as head injury(non-AD dementia: aHR = 1.51, 95% CI = 1.28–1.77; AD; aHR = 2.22, 95% CI = 1.16–4.22) and depression (non-AD dementia: aHR = 1.88, 95% CI = 1.68–2.11; AD; aHR = 1.83, 95% CI = 1.06–3.14), in contributing to the development of non-AD dementia and AD.

Table 4. Hazard ratios of non- Alzheimer's disease dementia and Alzheimer's disease in association with gender, age, irritable bowel syndrome and dementia-related comorbidities in univariate and multivariate Cox regression models.


According to our research, this population-based study is the first to assess the association between IBS and subsequent dementia. The explanatory power of our statistical analysis is supported by the 12-year observation period and large national database, containing a representative cohort of 1 000 000 enrollees inTaiwan’s NHI program. Moreover, the literature investigating the relationship between IBS and dementia in humans is limited by small samples. Cognitive impairment is typically confirmed according to brain morphology assessment by using magnetic resonance imaging or cognitive ability assessment by using questionnaires, glucocorticoids analysis, or models for neuropsychological testing. Our study is the first epidemiological study involving humans to demonstrate a correlation with an increased risk of dementia following IBS diagnosis [1215].

Taiwan’s NHI program, which provides access to affordable healthcare facilities, may have contributed to the overestimation of the prevalence of IBS in our study. However, we observed no sex difference insusceptibility to IBS between the IBS and non-IBS patients in this study, which supports the findings of previous studies investigating IBS in Asian populations, including those in Taiwan [3, 16]. In addition, we found no evidence that patients aged<50 years are particularly vulnerable to IBS development. By contrast, most epidemiological studies in Western countries have shown that IBS is more prevalent among women, particularly those who are <50 years old [17]. Estrogen might explain the susceptibility of female and younger patients to IBS in Western countries because it can increase the severity of visceral hyperalgesia and inhibit colonic motility [18,19]. Nevertheless, in addition to hormone factors, neuropsychological factors might also affect the clinical symptoms of IBS.

Our results show that compared with the patients in the non-IBS cohort, those in the IBS cohort tended to have more comorbidities, namely diabetes, hypertension, stroke, CAD, head injury, depression, and epilepsy. However, although the prevalence of health-care-related illnesses was higher among the patients with IBS, the risk of dementia remained higher in this cohort than in the non-IBS cohort following adjustment for diabetes, hypertension, stroke, CAD, head injury, depression, and epilepsy. Our study supports that the IBS cohort had more health-care-related illnesses. The reason for more prevalence of health-care-related illnesses in IBS patients remains unclear, but the literature has suggested that IBS patients are more vulnerable to psychosocial stress to have more medical consultations for GI symptoms or physical comorbidities [2022]. The underlying physiological mechanism responsible for more comorbidities in patients with IBS also remains unclear, although a previous study postulated that alterations in plasticity, neurogenesis, catecholaminergic neurotransmission, and gut microbiota are potential mechanisms [23].

In the present study, dementia incidence increased with age, was higher among men, and tended to coincide with a higher comorbidity incidence. The patients >50 years demonstrated a greater risk of dementia, increasing progressively with age from 13.0 (50–64-years) to 85.5 (≥65 years). However, the prevalence of dementia-associated comorbidity might have been underestimated because patients with dementia tend to have limited access to medical services. The reasons for the higher risk of comorbidity with dementia may include low accessibility to medical services because of poor communication, inadequate nursing care or intake, locomotion impairment or psychiatric disturbance following neurodegeneration, and dementia caused by comorbidity [24].

The association between IBS and dementia in our study may be due to their shared pathophysiological mechanisms. First, the mechanisms associated with IBS are complex and may include environmental and host factors [1]. Environmental factors include early life stressors, food intolerance, antibiotics, and enteric infection; whereas, host factors include altered pain perception, dysbiosis, increased gut permeability, activation of gut immune system, visceral hypersensitivity, and altered brain-gut interaction. On the whole, an abnormal bidirectional interaction through the brain—gut axis has been proposed as one of the possible mechanisms to explain the correlation between IBS and deregulated brain or behavior performance. The byproduct of gut dysbiosis can access the brain through cytokines released from mucosal immune cells, gut hormones released from enteroendocrine cells, or afferent neural pathways of the ENS influencing brain function and behavior. In addition, stress and emotional disturbance can cause gut dysbiosis and affect the gut physiology through the release of stress hormones or regulation of neuroendocrine transmitters [25]. Second, bacterial colonization and gut inflammation are detected by the afferent component of the vagus nerve, and the efferent response is communicated via vagal anti-inflammatory output [26,27]. Animal studies have suggested that the vagus nerve is the main route for transmitting cytokine signals to the brain, inducing neuroinflammation and potentiating neurotoxic substances [28,29]. IBS may increase lipopolysaccharide, complement factor, acute-phase protein, and proinflammatory cytokine levels in the brain, which have been implicated in the pathogenesis of dementia [30,31, 32]. Third, the hippocampus and cerebral cortex are regarded as the main foci for amyloid deposition following neuroinflammation, exacerbating cognitive dysfunction and increasing vulnerability to dementia [33, 34]. Moreover, the cerebellum is strongly related to cholinergic function and astroglial activation after neuroinflammation in the cerebellum, contributing to cognitive impairment in IBS [35].

Furthermore, the association between IBS and dementia in this study might be caused by shared risk factors since the prevalence of risk factors for dementia was higher in the patients with IBS than in those without IBS. However, we have adjusted for the possible dementia-associated factors, and it is reasonable to conclude that the correlation between an increased risk of dementia and IBS was likely to be caused by the effects of IBS status (Table 2). Our results indicate that the effect of IBS on the relative risk of dementia peaks between age 50–64 and then decreases after age 65, which might be due to increased prevalence of other dementia-associated risk factors in older patients. The results from our subgroup analyses with stratification of comorbidities could validate our results. We could not ascertain the temporal association between the occurrence of IBS and dementia. However, our results suggest the risk of dementia increases with the increment of follow-up duration, rather than in the immediate days, in patients with IBS. Overall, our results indicate a possible causal association between IBS and dementia, and suggest that IBS is a risk factor for dementia. However, our results showed that IBS may be less influential than those traditional dementia-associated risk factors such as aging, diabetes, hypertension, stroke, head injury, depression, and epilepsy, in contributing to the development of dementia.

Several limitations were observed during the course of our study. First, we were concerned about the validity of the IBS and dementia diagnoses among the patients enrolled in our study. However, the ICD-9-CMdiagnostic codes made based on Rome criteria for IBS and Diagnostic and Statistical Manual of Mental Disorders 4th edition(DSM-IV)for dementia are widely used in Taiwan, and the Bureau of National Health Insurance requires medical experts to regularly audit insurance claims in Taiwan. The NHI program has been monopolistically operated by the Taiwan government since 1995, and the accuracy of diagnosis were judged and determined by related specialists and physicians. The hospitals and doctors would be punished to pay a lot of penalty if they were judged to be incorrect in making the diagnoses. Therefore, the diagnoses of osteoporosis and dementia coded in this study should be correct and reliable. To ensure accurate diagnosis, we included only cases in which medical care was administered for IBS and dementia, either through outpatient visits or hospitalization, at least three times. Second, bias may have resulted from patients with IBS seeking medical care more frequently compared with patients without IBS, increasing the likelihood of dementia or comorbidity diagnosis during follow-up. Moreover, certain potentially confounding factors could not be verified because the NHIRD does not contain detailed information related to the lifestyle, socioeconomic status, and the family history of patients. However, after adjustment for the comorbidities of diabetes, hypertension, stroke, CAD, head injury, depression, and epilepsy, the risk of dementia among the patients with IBS remained higher than that among the patients in the non-IBS cohort. Finally, patients who are not enrolled in the NHI program were not included in our study population. However, Taiwan’s NHI program provides coverage for over 99% of the national population.

In conclusion, this nationwide population-based cohort study shows that IBS is associated with a higher risk of dementia and this effect is obvious only in patients who are ≥50 years old. Both IBS and dementia are independently related to a higher prevalence of healthcare-related illnesses. No difference in sex was observed between the IBS and non-IBS cohorts.


This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW104-TDU-B-212-113002); China Medical University Hospital, Academia Sinica Taiwan Biobank, Stroke Biosignature Project (BM104010092); NRPB Stroke Clinical Trial Consortium (MOST 103-2325-B-039–006); Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease Foundation, Taipei, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.

Author Contributions

Conceived and designed the experiments: C-HC C-HK. Analyzed the data: C-HC C-LL C-HK. Wrote the paper: C-HC C-LL C-HK. Administrative support: C-HK; Collection and assembly of data: C-HC C-LL C-HK; Final approval of manuscript: C-HC C-LL C-HKao.


  1. 1. Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015;313: 949–958. pmid:25734736
  2. 2. Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, et al. Asian consensus on irritable bowel syndrome. J GastroenterolHepatol. 2010;25: 1189–1205.
  3. 3. Lu CL, Chen CY, Lang HC, Luo JC, Wang SS, Chang FY,et al. Current patterns of irritable bowel syndrome in Taiwan: the Rome II questionnaire on a Chinese population. Aliment PharmacolTher.2003;18: 1159–1169.
  4. 4. Tang YR, Yang WW, Wang YL, Lin L. Sex differences in the symptoms and psychological factors that influence quality of life in patients with irritable bowel syndrome. Eur J Gastroenterol.2012;24: 702–707.
  5. 5. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, et al. Irritable bowel syndrome, health care use, and cost: A U.S. managed care perspective. Am J Gastroenterol.2003;98: 600–607. pmid:12650794
  6. 6. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditure. GastroenterolClin North Am.2011;40: 11–19.
  7. 7. Vandvik PO, Wilhelmsen I,Ihleback C, Farup PG. Comorbidity of irritable bowel syndrome in general practice: a striking feature with clinical implication. Aliment PharmacolTher. 2004;20: 1195–1203.
  8. 8. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: A microbiome-gut-brain axis disorder? World J Gastroenterol. 2014;20: 14105–14125. pmid:25339800
  9. 9. Clarke G, Quigley EM, Cryan JF,Dinan TG. Irritable bowel syndrome: towards biomarker identification. Trends Mol Med. 2009;15: 478–489. pmid:19811951
  10. 10. Mckhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendation from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement.2011;7: 263–269.
  11. 11. Database NHIR. Taiwan. Available: Accessed 2015.
  12. 12. Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Naliboff BD, Bushnell MC, et al. Regional gray matte changes in brains of patients with irritable bowel syndrome. Gastroenterology.2010;139: 48–57. pmid:20347816
  13. 13. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology.2011;140: 91–100. pmid:20696168
  14. 14. Piche M, Chen JI, Roy M, Poitras P, Bouin M, Rainville P. Thicker posterior insula is associated with disease duration in women with irritable bowel syndrome (IBS) whereas thicker orbitofrontal cortex predicts reduced pain inhibition in both IBS patients and controls. J Pain. 2013;14: 1217–1226. pmid:23871603
  15. 15. Kennedy PJ, Clarke G, O’Nill A, Groeger JA, Quigley EMM, Shanahan F, et al. Cognitive performance in irritable bowel syndrome: evidence of a stress-related impairment in visuospatial memory. Psychol Med. 2014; 44: 1553–1566. pmid:23985155
  16. 16. Gwee KA, Lu CL, Ghoshal UC. Epidemiology of irritable bowel syndrome in Asia: Something old, something new, something borrowed. J GastroenterolHepatol. 2009;24: 1601–1607.
  17. 17. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. ClinEpidemiol. 2014;6: 71–80.
  18. 18. Hogan AM, Kennelly R, Collins D, Baird AW, Winter DC. Oestrogen inhibits human motility by a non-genomic cell membrane receptor-dependent mechanism. Br J Surg 2009; 96: 817–822. pmid:19405165
  19. 19. Sanoja R, Cervero F. Estrogen-dependent abdominal hyperalgesia induced by ovariectomy in adult mice: a model of functional abdominal pain. Pain.2005;118: 243–253. pmid:16202534
  20. 20. Heaton KW, O’Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology. 1992;304: 87–90.
  21. 21. Drossman DA, Mckee DC, Sandler RS, Mitchell CM, Lowman BC, Burger AL. Psychosocial factors in irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology.1988;95: 701–708. pmid:3396817
  22. 22. Whitehead WE, Bosmajian L, Zonderman AB, Costa PT, Schuster MM.Symptoms of psychological distress associated with irritable bowel syndrome. Comparison of community and medical clinic samples. Gastroenterology. 1988;95: 709–714. pmid:3396818
  23. 23. Daulatzai MA. Chronic functional bowel syndrome Enhances gut-brain axis dysfunction, neuroinflammation, cognitive impairment, and vulnerability to dementia. Neurochem Res.2014;39: 624–644. pmid:24590859
  24. 24. Bauer K, Schwarzkopf L, Graessel E, Holle R. A calims data-based comparison of comorbidity in individuals with and without dementia. BMC Geriatrics.2014;14: 10. pmid:24472217
  25. 25. Thakur AK, Shakya A, Husain GM, Emerald M, Kumar V. Gut-microbiota and mental health: Current and future perspectives. J PharmacolClinToxicol.2014;2: 1016.
  26. 26. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med.2003;9: 125–134. pmid:14571320
  27. 27. Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med.2005;202: 1023–1029. pmid:16216887
  28. 28. Hansen MK, Taishi P, Chen Z, Krueger JM. Vagotomy blocks the induction of interleukin-1 beta (IL-1 beta) mRNA in the brain of rats in response to systemic IL-1 beta. J Neurosci.1998;18: 2247–2253. pmid:9482809
  29. 29. Hansen MK, Nguyen KT, Goehler LE, Gaykema RP, Fleshner M, Maier SF, et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1 beta protein in rats. AutonNeurosci.2000;85: 119–126.
  30. 30. Agostinho P, Cunha RA, Oliveria C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Curr Pharm Des.2010;16: 2766–2778. pmid:20698820
  31. 31. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, et al. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation. 2012;9: 151. pmid:22747753
  32. 32. Daulatzai MA. Obesity and gut’s dysbiosis promote neuroinflammation, cognitive impairment, and vulnerability to Alzheimer’s disease: New directions and therapeutic implications. J Mol Genet Med. 2014;S1: 005.
  33. 33. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, et al.Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation.2008;5: 37. pmid:18759972
  34. 34. Frings L, Spehl TS, Weber WA, Hull M, Meyer PT. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia. J Nucl Med.2013;54: 1909–1914. pmid:24101684
  35. 35. Rosenberger C, Thurling M, Forsting M, Elsenbruch S, Timmann D, Gizewski ER. Contributions of the cerebellum to disturbed central processing of visceral stimuli in irritable bowel syndrome. Cerebellum.2013;12: 194–198. pmid:22910984